These insights justify the ongoing clinical trials of histone-modulating drugs: e.g., panobinostat (a pan-HDAC inhibitor) was tested in recurrent GBM with some benefit in combination with bevacizumab (Zhang et al., 2025); and histone methylation drugs like tazemetostat (EZH2 inhibitor) are being tried in both adult and pediatric high-grade gliomas. Here, HDAC9 is linked to glioblastoma.